# Interlinked Pathways: Exploring the Bidirectional Impacts of Periodontitis and Metabolic Syndrome

**Authors:** Bandar M Barnawi, Maram M Alanazi, Fai A Al-Mutiri, Rahaf S Alqahtani, Madhawi S Al-harbi, Saud K Al-Raqqas, Waleed K Mahjoub, Mahdi M Alsetri, Ziyad M Al-Sultan, Ghadeer M Alghamdi, Ridha I Almutawah

PMC · DOI: 10.7759/cureus.67544 · Cureus · 2024-08-22

## TL;DR

This paper reviews how periodontitis and metabolic syndrome influence each other through shared inflammatory pathways.

## Contribution

The paper provides a comprehensive analysis of the bidirectional relationship between periodontitis and metabolic syndrome.

## Key findings

- Periodontitis and metabolic syndrome share pro-inflammatory mediators that worsen both conditions.
- The pathophysiological mechanisms of metabolic syndrome components impact periodontitis severity and vice versa.

## Abstract

Metabolic syndrome (MBS) and periodontitis are distinct conditions with overlapping and unique risk factors. Periodontitis is a chronic destructive disease of the periodontium, driven by alterations in the host immune-inflammatory response to virulent periodontal pathogens. MBS is characterized by various abnormalities, including visceral abdominal obesity, dyslipidemia (low high-density lipoprotein (HDL) and high triglyceride (TG) levels), hypertension, and hyperglycemia. These factors collectively increase the risk of atherosclerotic cardiovascular disease (CVD) and diabetes. Several pro-inflammatory mediators are involved in the pathogenesis of periodontitis and MBS, and the deleterious bidirectional effects of these mediators exacerbate the severity and progression of both conditions. This comprehensive review focuses on the intricate relationship between MBS and periodontitis. Specifically, it explores the pathophysiological mechanisms of each disease component of MBS and its impact on periodontitis, and vice versa.

## Linked entities

- **Chemicals:** triglyceride (PubChem CID 5460048)
- **Diseases:** periodontitis (MONDO:0005076), metabolic syndrome (MONDO:0000816), atherosclerotic cardiovascular disease (MONDO:1060134), diabetes (MONDO:0005015)

## Full-text entities

- **Diseases:** CVD (MESH:D002318), hypertension (MESH:D006973), diabetes (MESH:D003920), visceral abdominal obesity (MESH:D056128), hyperglycemia (MESH:D006943), dyslipidemia (MESH:D050171), MBS (MESH:D024821), Periodontitis (MESH:D010518), atherosclerotic cardiovascular disease (MESH:D050197), inflammatory (MESH:D007249)
- **Chemicals:** TG (MESH:D014280)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11416629/full.md

## References

135 references — full list in the complete paper: https://tomesphere.com/paper/PMC11416629/full.md

---
Source: https://tomesphere.com/paper/PMC11416629